Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 6

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 6
---
HURA stockholders and the Merger Agreement Proposal is approved by Kineta stockholders. Your vote is important. Whether or not you plan to attend the applicable special meeting and regardless of the number of shares you own, your careful consideration of, and vote on, the applicable proposals is important, and you are encouraged to vote promptly. The failure to vote for the Authorized Share Increase Proposal will have the same effect as a vote “AGAINST” the Authorized Share Increase Proposal. The failure to vote for the Merger Agreement Proposal will have the same effect as a vote “AGAINST” the proposal to adopt the Merger Agreement.

The accompanying joint proxy statement/prospectus provides you with important information about the special meetings, the Mergers, and each of the proposals. WE ENCOURAGE YOU TO READ THE ENTIRE DOCUMENT CAREFULLY, IN PARTICULAR THE “ RISK FACTORS” SECTION BEGINNING ON PAGE 45 FOR A DISCUSSION OF RISKS RELEVANT TO THE MERGERS.

After reading the accompanying joint proxy statement/prospectus and its annexes, please make sure to vote your shares promptly by completing, signing and dating the accompanying proxy card and returning it in the enclosed prepaid envelope or by voting by telephone or through the Internet by following the instructions on the accompanying proxy card. If you hold shares through an account with a bank, broker, trust or other nominee, please follow the instructions you receive from it to vote your shares.

Thank you in advance for your continued support and your consideration of this matter. We look forward to the successful completion of the Mergers.**

| Sincerely,                                   |     | Sincerely,                                   |
| Dr. James Manuso                             |     | Dr. Shawn P. Iadonato                        |
| Chairman of the Board of Directors of TuHURA |     | Chairman of the Board of Directors of Kineta |

Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of the Mergers or the TuHURA Common Stock to be issued in the Mergers or determined if this joint proxy statement/prospectus is accurate or complete. Any representation to the contrary is a criminal offense. The accompanying notices of special meetings of stockholders and joint proxy statement/prospectus are dated [●], 2025, and are first being mailed to the stockholders of TuHURA and Kineta on or about [●], 2025.

TuHURA Biosciences, Inc. 10500 University Center Dr